Catalyst Pharmaceuticals (NASDAQ:CPRX) Given New $30.00 Price Target at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price lifted by Truist Financial from $25.00 to $30.00 in a report released on Friday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

CPRX has been the subject of several other reports. HC Wainwright restated a buy rating and set a $26.00 target price on shares of Catalyst Pharmaceuticals in a research report on Monday, June 3rd. Oppenheimer reissued an outperform rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a hold rating to a buy rating in a report on Friday, June 7th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Buy and an average price target of $28.83.

Catalyst Pharmaceuticals Trading Up 1.0 %

Shares of Catalyst Pharmaceuticals stock traded up $0.18 during trading on Friday, reaching $18.48. The company’s stock had a trading volume of 2,888,357 shares, compared to its average volume of 1,290,174. Catalyst Pharmaceuticals has a one year low of $11.55 and a one year high of $18.99. The stock has a 50-day moving average price of $16.14 and a two-hundred day moving average price of $15.60. The stock has a market capitalization of $2.18 billion, a P/E ratio of 34.22 and a beta of 0.70.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The business had revenue of $98.51 million for the quarter, compared to analysts’ expectations of $97.24 million. As a group, sell-side analysts anticipate that Catalyst Pharmaceuticals will post 1.63 EPS for the current fiscal year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the sale, the insider now owns 18,427 shares in the company, valued at $296,121.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Molly Harper sold 5,333 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $16.30, for a total value of $86,927.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carmen Jeffrey Del sold 7,541 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $16.07, for a total transaction of $121,183.87. Following the sale, the insider now directly owns 18,427 shares of the company’s stock, valued at approximately $296,121.89. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,197 shares of company stock worth $1,777,560. Insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC increased its position in Catalyst Pharmaceuticals by 139.5% in the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after acquiring an additional 1,587,794 shares during the period. Boston Partners raised its stake in Catalyst Pharmaceuticals by 965.2% in the 4th quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock valued at $25,610,000 after acquiring an additional 1,396,930 shares during the period. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the period. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $11,463,000. Finally, Kennedy Capital Management LLC boosted its holdings in Catalyst Pharmaceuticals by 101.1% in the 1st quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock worth $16,924,000 after buying an additional 533,802 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.